← back to search

Iris Helfrich

West Cancer Center · DE
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Angiogenesis and VEGF in Cancer, Cancer Cells and Metastasis, Radiopharmaceutical Chemistry and Applications, and Cancer, Hypoxia, and Metabolism.
h-index
34
citations
5,008
works
151
NIH funding
primary concept
Medicine
email

Recent publications

Identification and characterization of tertiary lymphoid structures in brain metastases
Acta Neuropathologica Communications 2025cited by 8position: middledoi
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
Clinical and Translational Medicine 2025cited by 2position: lastdoi
Serpins A1/A3 within tumor-derived extracellular vesicles support pro-tumoral bias of neutrophils in cancer
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: middledoi
T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels
Immunity 2024cited by 18position: middledoi
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma
British Journal of Dermatology 2024cited by 6position: middledoi
Identification and characterization of tertiary lymphoid structures in brain metastases
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 1position: middledoi
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Nature Cancer 2023cited by 59position: middledoi
Active Remodeling of Capillary Endothelium via Cancer Cell–Derived MMP9 Promotes Metastatic Brain Colonization
Cancer Research 2023cited by 46position: middledoi
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
Journal for ImmunoTherapy of Cancer 2023cited by 29position: lastdoi
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Nature Cancer 2023cited by 2position: middledoi
Persister state-directed transitioning and vulnerability in melanoma
Nature Communications 2022cited by 35position: middledoi
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Journal for ImmunoTherapy of Cancer 2022cited by 19position: middledoi
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
European Heart Journal 2021cited by 156position: middledoi
<scp>SIRT1</scp>‐mediated deacetylation of FOXO3a transcription factor supports pro‐angiogenic activity of interferon‐deficient tumor‐associated neutrophils
International Journal of Cancer 2021cited by 34position: middledoi
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain
Frontiers in Immunology 2020cited by 38position: lastdoi
Persister state-directed transitioning and vulnerability in melanoma
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 4position: middledoi
The Janus-faced role of KDM5B heterogeneity in melanoma: differentiation as a situational driver of both growth arrest and drug-resistance
2020cited by 1position: middle
Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma
Cancers 2019cited by 45position: firstdoi
Targeting the “undruggable” RAS - new strategies - new hope?
Cancer Drug Resistance 2019cited by 7position: lastdoi
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression
Nature Communications 2017cited by 44position: middledoi
Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging
Science Translational Medicine 2015cited by 301position: middledoi
CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival
Cancer Research 2015cited by 29position: lastdoi
Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
The Journal of Experimental Medicine 2013cited by 163position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Dirk Schadendorf · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori12 papers (2013–2025)Anna S. Berghoff · Universitätszahnklinik Wien4 papers (2023–2025)Joachim Klode · Essen University Hospital3 papers (2015–2020)Jörg Felsberg · Düsseldorf University Hospital3 papers (2020–2025)Benedikt Brors · German Cancer Research Center3 papers (2020–2025)Sadaf S. Mughal · German Cancer Research Center3 papers (2020–2025)Alexander Roesch · German Cancer Research Center3 papers (2015–2025)Dana Westphal · Helmholtz-Zentrum Dresden-Rossendorf2 papers (2023–2024)Jadranka Macas · Goethe University Frankfurt2 papers (2024–2025)Jadwiga Jabłońska · German Cancer Research Center2 papers (2021–2025) · 2 papers (2021–2025)Selma Ugurel · Kliniken Essen-Mitte2 papers (2021–2024)Marc C. Schubert · The University of Texas MD Anderson Cancer Center2 papers (2023–2024) · 2 papers (2015–2019) · 2 papers (2021–2025)Britta Mörchen · West Cancer Center2 papers (2019–2021)Karl Köhrer · Life Science Center Düsseldorf (Germany)2 papers (2024–2025)Silja Schlue · German Cancer Research Center2 papers (2024–2025)Chanté D. Mayer · Heidelberg University2 papers (2023–2024)Harriet Wikman · Universität Hamburg2 papers (2024–2025)